Download PDF
Arthritis und Rheuma 2005; 25(03): 136-140
DOI: 10.1055/s-0037-1618500
Innovationen auf dem Prüfstand
Schattauer GmbH

Separationsverfahren bei Autoimmunerkrankungen und rheumatischen Prozessen

Extracorporal therapy in autoimmune diseases and rheumatic processes
Jürgen Rech
1   Universität Erlangen-Nürnberg, Medizinische Klinik III
› Author Affiliations
Further Information

Publication History

Publication Date:
23 December 2017 (online)

    Permissions and Reprints

Zusammenfassung

Neben den deutlich verbesserten Behandlungsmöglichkei-ten und der damit verbesserten Prognose von Autoimmunerkrankungen durch den Einsatz von neuen Immunsuppressiva und Biologicals (monoklonale Antikörper wie z. B. Anti-TNF-Therapie) waren bereits in den 70er-Jahren die Extrakorporalverfahren wie z. B. therapeutischer Plasma-austausch und Immunadsorption Hoffnungsträger, die in der Vergangenheit die Erwartungen in ihrer Wirkung und Anwendung nicht erfüllten. Seither wird der Einsatz von Ex-trakorporalverfahren in der Rheumatologie kontrovers dis-kutiert.

Die Weiterentwicklung der spezifischen Extrakorporalverfahren (Immunadsorption, Photopherese) gegebenenfalls zusammen mit beispielsweise Biologicals ist eine neue Grundlage für die Möglichkeit des Einsatzes in der Therapie von Autoimmunerkrankungen. Ein deutlich reduziertes Nebenwirkungsprofil der Extrakorporalverfahren trägt dazu wesentlich bei.

Summary

In addition to the dramatic improvement in available therapies, and consequently the improved prognosis of autoimmune diseases through the use of new immunosuppressive agents and, for instance, biologicals (such as monoclonal antibodies e.g. anti-TNF therapy), the hope for the role of extracorporal therapy (e.g. therapeutic plasma exchange and immunoadsorption) has lagged behind since the seventies. Since then, the therapeutic need for extracorporal therapy has been controversially discussed. With improved specific extracorporal therapies, e.g. immunoadsorption and photopheresis, and a possible combination with biologicals, it currently seems to be a new treatment optioninautoimmunediseases, than kstotherelatively few side effects associated with extracorporal therapy.

Schlüsselwörter

Immunadsorption - therapeutischer Plasmaaustausch - Photopherese - rheumatoide Arthritis - systemischer Lupus erythematodes - Pemphigus vulgaris

Keywords

Immunoadsorption - plasma exchange - rheumatoid arthritis - systemic lupus erythematosus - pemphigus vulgaris
 

  • Literatur

  • 1 Abel JJ., Rowntree LC., Turner BB. Plasma removal with return of corpuscles. J Pharmacol Exp Ther 1914; 5: 621-41.
    Google Scholar
  • 2 Braun N., Kadar JG., Risler T. Therapeutic immunoadsorption – its role in clinical practice. Transfus Sci 1998; 19 (Suppl.) 65-9.
    CrossrefPubMedGoogle Scholar
  • 3 Clark WF., Balfe JW., Cattran DC. et al Long-Term Plasma Exchange in Patients with Systemic Lupus Erythematosus and Diffuse Proliferative Glomerulonephritis. Plasma Ther Transfus Technol 1984; 5: 353-60.
    Google Scholar
  • 4 Derksen RH., Hene RJ., Kallenberg CG. et al Prospective multicentre trial on the short-term effects of plasma exchange versus cytotoxic drugs in steroid-resistant lupus nephritis. Netherlands Journal of Medicine 1988; 33: 168-77.
    PubMedGoogle Scholar
  • 5 Euler HH., Schroeder JO., Harten P., Zeuner RA., Gutschmidt HJ. Treatment-Free Remission In Severe Systemic Lupus Erythematosus Following Synchronization of Plasmapheresis with Subsequent Pulse Cyclophosphamide. Arthritis and Rheumatism 1994; 37 (12) 1784-94.
    CrossrefPubMedGoogle Scholar
  • 6 Euler HH., Schroeder JO., Löffler H., Christophers E. Synchronization of plasmapheresis and pulse cyclophosphamide in pemphigus vulgaris. Arch dermatol 1987; 123: 1205-10.
    CrossrefPubMedGoogle Scholar
  • 7 Felson DT., Anderson JJ., Boers M. et al The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36 (06) 729-40.
    CrossrefPubMedGoogle Scholar
  • 8 Gaubitz M., Schneider KM. Immunoadsorption in systemic lupus erythematosus: different techniques and their current role in medical therapy. Therap Apher Dial 2003; 7 (02) 183-8.
    CrossrefPubMedGoogle Scholar
  • 9 Hashimoto H., Tsuda H., Kanai Y., Kobayashi S. Selective Removal of Anti-DNA and Anticardiolipin Antibodies by Absorbent Plasmapheresis using Dextran Sulfate Columns in Patients with Systemic Lupus Erythematosus. The Journal of Rheumatology 1991; 18 (04) 545-51.
    PubMedGoogle Scholar
  • 10 Haupt WF., Rosenow F., van der Ven C., Birkmann C. Immunoadsorption in Guillain-Barre syndrome and myasthenia gravis. Ther Apher 2000; 4 (03) 195-7.
    CrossrefPubMedGoogle Scholar
  • 11 Heald PW., Perez MI., Christensen I. et al. Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience. Yale J Biol Med 1989; 62 (06) 629-38.
    PubMedGoogle Scholar
  • 12 Hiepe F., Pfuller B., Wolbart K. et al. A multifunctional ligand for a new immunoadsorption treatment. Ther Apher 1999; 3 (03) 246-51.
    PubMedGoogle Scholar
  • 13 Hughes GR. Plasma exchange (plasmapheresis). Agents Actions Suppl 1980; 7: 62-5.
    Google Scholar
  • 14 Jones JV., Cumming RH., Bucknell RC., Asplin CM. Plasmapheresis in the Management of Acute Systemic Lupus erythematosus. The Lancet 1976; 3: 709-11.
    Google Scholar
  • 15 Jones JV., Robinson MF., Parciany RK. et al Therapeutic Plasmapheresis in systemic lupus erythematosus. Arthritis and Rheumatism 1981; 24 (09) 1113-20.
    CrossrefPubMedGoogle Scholar
  • 16 Lewis EJ., Hunsicker LG., Shu-Ping Lan. et al for the Lupus Nephritis Collaborative Study Group. A controlled Trial of Plasmapheresis Therapy in Severe Lupus Nephritis. The New England Journal of Medicine 1992; 326: 1373-9.
    CrossrefPubMedGoogle Scholar
  • 17 Luftl M., Stauber A., Mainka A. et al Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 2003; 149 (03) 598-605.
    CrossrefPubMedGoogle Scholar
  • 18 Lupus Plasmapheresis Study Group (LPSG) Clark WF., Dau PC., Euler HH. et al. Plasmapheresis and Subsequent Pulse Cyclophosphamide Versus Pulse Cyclophosphamide Alone in Severe Lupus. Journal of Clinical Apheresis 1991; 6: 40-7.
    CrossrefPubMedGoogle Scholar
  • 19 Mistry-Burchardi N., Schönermarck U., Samtleben W. Apheresis in Lupus Nephritis. Therapeutic Apheresis 2001; 5 (03) 161.
    CrossrefPubMedGoogle Scholar
  • 20 Rech J., Wollenhaupt J., Kalden JR. et al. and the RA-1 Photopheresis Study Group. A phase II, MULTICENTER, Randomized Double-Blind, “Sham” pheresis-Controlled, study of Extracorporal photoimmune therapy (ECP) with UVADEX for the treatment of rheumatoid arthritis (RA) in Patients (pts) who have an inadequate response to disease-modifying antirheumatic Drugs (DMARDs) and biological agents; Abstract submitted EULAR. 2005
    PubMedGoogle Scholar
  • 21 Ruocco V., Astarita C., Pisani M. Plasmapheresis as an alternative or adjunctive therapy in problem cases of pemphigus. Dermatologica 1984; 168: 219-23.
    CrossrefPubMedGoogle Scholar
  • 22 Schwab PJ., Fahey JL. Treatment of Waldenstrom`s macroglobulinemia by plasmapheresis. N Engl J Med 1960; 574-9.
    PubMedGoogle Scholar
  • 23 Skoog WA., Adams WS. Plasmapheresis in a case of Waldenstrom`s macroglobulemia (Abstract). J Clin Res 1959; 7: 96.
    Google Scholar
  • 24 Suzuki K., Hara M., Harigai M. et al. Continuous Removal of Anti-DNA Antibody, using a new extracorporal Immunadsorption System, in Patients with systemic lupus erythematosus. Arthritis and Rheumatism 1991; 34 (12) 1546-51.
    PubMedGoogle Scholar
  • 25 Toepfer M., Sitter T., Burchardt C. et al. Klinische Immunadsorption. Dtsch med Wschr 1999; 124: 461-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Wallace DJ. Plasmapheresis in Rheumatic Diseases. Biomed Pharmacother 1986; 40 (08) 284-6.
    PubMedGoogle Scholar
  • 27 Wie N., Klippel JH., Huston DP. et al Randomized Trial of plasma Exchange in mild Systemic Lupus Erythematosus. The Lancet 1983; 1 (08) 17-21.
    PubMedGoogle Scholar